H.C. Wainwright raised the firm’s price target on electroCore (ECOR) to $22 from $15 and keeps a Buy rating on the shares after the firm ...
Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...
H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes ...
H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the ...
On Thursday, SpringWorks Therapeutics Inc (SWTX) stock saw a modest uptick, ending the day at $36.55 which represents a slight increase of $1.84 or 5.30% from the prior close of $34.71. The stock ...
MARA shares down as Q3 earnings miss estimates with lower revenue and adjusted loss, analysts maintain mixed views and price ...
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $1.09 which represents a decrease of $-0.10 or -8.40% from the prior close of $1.19. The stock opened at $1.18 ...
H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...
In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback